

Online Data Supplement

Incidence, risk factors and outcomes of delirium in mechanically ventilated adults

Sangeeta Mehta, Deborah Cook, John W. Devlin, Yoanna Skrobik, Maureen Meade, Dean Fergusson, Margaret Herridge, Marilyn Steinberg, John Granton, Niall Ferguson, Maged Tanios, Peter Dodek, Robert Fowler, Karen Burns, Michael Jacka, Kendiss Olafson, Ranjeeta Mallick, Steven Reynolds, Sean Keenan, and Lisa Burry, for the SLEAP Investigators and the Canadian Critical Care Trials Group

Table of Contents	Page
SLEAP Clinical Collaborators	2
Table E1. Comparison of presence of delirium, coma, and antipsychotic drug use of SLEAP groups	3

SLEAP Clinical Collaborators

Canadian Investigators:

- Dr. Sangeeta Mehta (Lead), Dr. Lisa Burry, Marilyn Steinberg, Dr. Stephen Lapinsky, Cheryl Ethier; Mount Sinai Hospital, Toronto
- Dr. John Granton, Dr. Niall Ferguson, Dr. Margaret Herridge, Paulina Farias, Andrea Matte, Nancy Brockest, Lucy Mironyuk; University Health Network
- Dr. Deborah Cook, Andrea Tkaczyk, Ellen McDonald, France Clarke; St. Joseph's Healthcare, Hamilton
- Dr. Robert Fowler, Nicole Marinoff, Derek Parsotam, Karen Code; Sunnybrook Health Sciences Centre, Toronto
- Dr. Peter Dodek, Betty Jean Ashley, Sheilagh Mans; St. Paul's Hospital, Vancouver
- Dr. Karen Burns, Orla Smith, Kerri Porretta, Yoon Lee, Vicki Wen, Beth Fry; St. Michael's Hospital, Toronto
- Dr. Maureen Meade, Lori Hand; Hamilton Health Sciences, Hamilton General Hospital, Hamilton
- Dr. Michael Jacka, Leeca Sonnema, Carey Kinjerski, Tamara Kreidl; Walter C. Mackenzie Health Sciences Centre, Edmonton
- Dr. Kendiss Olafson, Wendy Janz; Health Sciences Centre, Winnipeg
- Dr. Yoanna Skrobik, Johanne Harvey; Maisonneuve Rosemount, Montreal
- Dr. Steven Reynolds, Dr. Sean Keenan, Miroslav Svetik; Royal Columbian Hospital, New Westminster
- Dr. Steven Reynolds, Dr. Sean Keenan, Dr. Ted Lawson, Sheilagh Mans; Surrey Memorial Hospital, Surrey
- Dr. Jim Kutsogiannis, Patricia Thompson; Royal Alexandra Hospital, Edmonton

U.S. Investigators:

- Dr. John W. Devlin, Dr. Erik Garpestad, Dr. Russ Roberts; Tuft's Medical Centre, Boston
- Dr. Maged Tanios, Hyunsoon Park; Long Beach Memorial Medical Centre, Long Beach

SLEAP Steering Committee: Sangeeta Mehta (Principal Investigator), Lisa Burry, Maureen Meade, Deborah Cook, Dean Fergusson, Paul Hebert, Karen Antoni, Marilyn Steinberg (Project Manager)

SLEAP Methods Center: Ranjeeta Mallick, Catherine Bordeleau, Jennie Cote, Dong Vo

Data Safety Monitoring Committee: Drs. Jesse Hall (chair), Scott Epstein, Rollin Brant

SLEAP Writing Committee: Sangeeta Mehta (Chair), Lisa Burry, Deborah J Cook, Maureen Meade.

Table E1. Comparison of presence of delirium, coma, and antipsychotic drug use of SLEAP groups

	All patients (N = 420)	Protocolized sedation and daily interruption (N=213)	Protocolized sedation (N=209)	P value
<i>DELIRIUM</i> ^a				
Patients with ≥ 1 day of delirium, N (%)	226 (58.1)	113 (58.8)	113 (57.4)	.76
Patient days with delirium, median (IQR)	1 (0,3)	1 (0,3)	1 (0,3)	.71
<i>COMA</i> ^b				
N patients (%)	137 (32.5)	66 (31.0)	71 (34.0)	.51
Patient days with coma, median (IQR)	0 (0,1)	0 (0,1)	0 (0,1)	.70
<i>ANTIPSYCHOTIC THERAPY</i> ^c				
Patients who received ≥ 1 dose, N (%)	106 (25.1)	52 (24.4)	54 (25.8)	.74
Days patients received ≥ 1 dose , median (IQR)	0 (0,1)	0 (0,0)	0 (0,1)	.44

P value represents comparison between protocolized sedation and daily interruption, and protocolized sedation groups.

^a Delirium was defined as ICDSC ≥ 4 at any time during the trial. No delirium was defined as ICDSC always <4.

^b Coma was defined as SAS score of 1 or 2, or RASS score of -5 or -4, for 4 or more contiguous hours during any study day.

^c Antipsychotic = haloperidol, olanzapine, quetiapine, risperidone.